AMBOSS receives 240 million euros

AMBOSS is strengthening its position as digital support for doctors worldwide. The company aims to grow further with a new financing round of 240 million euros

Berlin, March 26, 2025 - Medtech AMBOSS has closed a financing round of 240 million euros. The funds come from new investors such as KIRKBI, M&G Investments and Lightrock as well as from existing shareholders. The aim is to expand into further international markets and extend the range of services for nursing staff and other healthcare professionals.

Long-term investors on board

AMBOSS has recently transformed itself into a European Company (SE). The new investors are committed to long-term cooperation."Many of our new investors manage evergreen funds and will accompany us until a possible IPO and beyond," explains Benedikt Hochkirchen, co-founder and co-CEO of AMBOSS. The funds will be used for technology investments, new market segments and targeted acquisitions. AMBOSS had already acquired the nursing start-up Novaheal and NEJM Knowledge+ for US medical education in 2024.

Support for medical professionals worldwide

AMBOSS offers digital solutions for doctors and medical students. More than one million users in 180 countries use the platform for clinical decision-making and training. In Germany, every second inpatient treatment by doctors is supported by AMBOSS. In the USA, many medical students use the platform to prepare for exams. A quarter of the first US residents use AMBOSS to ensure better patient care.

Combination of medical knowledge and technology

The success of AMBOSS is based on the collaboration of medical and technology experts. The platform provides accurate recommendations for diagnosis and treatment based on current guidelines.

Technology will not replace doctors, but those who use it will shape the future of medicine

Dr. Madjid Salimi, Co-Founder and Co-CEO of AMBOSS

The new investors underline the importance of AMBOSS as a partner for medical professionals. Peter Bason from KIRKBI emphasizes:"AMBOSS has established itself as an important tool for medical students and professionals. We look forward to accompanying the company on its further growth path." The fresh funds will strengthen AMBOSS' financial base and enable future innovation and expansion. In the fall of 2024, we reported on the acquisition of Novaheal by Amboss.